Translational Psychiatry
September 19, 2017
A Ahnaou, H Huysmans, R Biermans et al.
Recently, the N-methyl-d-aspartate-receptor (NMDAR) antagonist ketamine has emerged as a fast-onset mechanism to achieve antidepressant activity, whereas its psychomimetic, dissociative and amnestic effects have been well documented to pharmacologically model schizophrenia features in rodents. Sleep-wake architecture, neuronal oscillations and network connectivity are key mechanisms supporting...
The Brown University Child & Adolescent Psychopharmacology Update
September 1, 2017
Ketamine has been used effectively for adults with major depressive disorder (MDD), studies have found. Although results of the medication, which is administered via infusion, only last a few days, some research suggests that treatments three times a week may prolong the effects.
Psychopharmacology
September 2017
Sanders A McDougall, Andrea E Moran, Timothy J Baum et al.
Ketamine is used by preadolescent and adolescent humans for licit and illicit purposes. The goal of the present study was to determine the effects of acute and repeated ketamine treatment on the unconditioned behaviors and conditioned locomotor activity of preadolescent and adolescent rats. To assess unconditioned behaviors, female and male rats were injected with ketamine (5-40 mg/kg), and...
Psychopharmacology
September 2017
Olakunle James Onaolapo, Olayemi Quyyom Ademakinwa, Temitayo Opeyemi Olalekan et al.
We studied the influence of zinc, haloperidol or olanzapine on neurobehaviour (open-field, radial arm maze and elevated plus maze) and brain antioxidant status in vehicle- or ketamine-treated mice, with the aim of ascertaining the potentials of zinc in counteracting ketamine's effects. Experiment 1 assessed the effects of zinc in healthy animals and the relative degrees of modulation of...
Biological Psychiatry
September 1, 2017
Wallace C. Duncan, Elizabeth E. Slonena, Nadia S. Hejazi et al.
The rapid clinical antidepressant effects of the glutamatergic modulator ketamine may be due to its ability to restore synaptic plasticity and related effects on sleep-wake and circadian systems. Preclinical studies indicate that ketamine alters expression of circadian clock-associated molecules, and clinical studies of ketamine on plasticity-related biomarkers further suggest an association...
Neuropsychopharmacology
August 29, 2017
Jerome H Taylor, Angeli Landeros‐Weisenberger, Catherine Coughlin et al.
Many patients with social anxiety disorder (SAD) experience inadequate symptom relief from available treatments. Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared the...
Current Psychiatry Reports
August 26, 2017
J. Krystal, Chadi G. Abdallah, Lynnette A. Averill et al.
Purpose of ReviewStudies of the neurobiology and treatment of PTSD have highlighted many aspects of the pathophysiology of this disorder that might be relevant to treatment. The purpose of this review is to highlight the potential clinical importance of an often-neglected consequence of stress models in animals that may be relevant to PTSD: the stress-related loss of synaptic...
Cell Reports
August 22, 2017
Oliver H Miller, Andreas Bruns, Imen Ben Ammar et al.
The NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant depression. Understanding how antagonism of NMDARs alters synapse and circuit function is pivotal to developing circuit-based therapies for depression. Using virally induced gene deletion, ex vivo optogenetic-assisted circuit analysis, and in vivo chemogenetics and...
Journal of Affective Disorders
August 15, 2017
Elizabeth D. Ballard, Kathleen E. Wills, Níall Lally et al.
Identifying clinical correlates associated with reduced suicidal ideation may highlight new avenues for the treatment of suicidal thoughts. Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine. This analysis sought to evaluate whether reductions in suicidal ideation after ketamine...
JAMA
August 14, 2017
Samuel T. Wilkinson, Gerard Sanacora
36 citations
This Viewpoint summarizes a number of important issues related to the clinical use of ketamine for the treatment of psychiatric disorders addressed in the consensus statement and provides suggestions for addressing remaining concerns.
Biological and Pharmaceutical Bulletin
August 1, 2017
Si-Jie Tan, Yan Wang, Ke Chen et al.
The purpose of the present study was to investigate whether ketamine's rapid antidepressant effects were associated with its anti-inflammatory actions and to explore the underlying molecular mechanism. Depressive-like behaviors was induced in mice using chronic restraint stress (CRS) method. Anti-depressive effects of ketamine were evaluated by forced swimming tests (FST) and sucrose preference...
L'Encephale
August 2017
B Romeo, W Choucha, P Fossati et al.
The aim of this review was to determine the clinical and biological predictors of the ketamine response. A systematic research on PubMed and PsycINFO database was performed without limits on year of publication. The main predictive factors of ketamine response, which were found in different studies, were (i) a family history of alcohol dependence, (ii) unipolar depressive disorder, and (iii)...
Journal of Clinical Psychopharmacology
August 2017
Maryam I Al Shirawi, Sidney H. Kennedy, Keith T. Ho et al.
The aim of the study was to assess the effectiveness, tolerability, and safety of oral ketamine as an antidepressant treatment in adults with treatment-resistant depression. We reviewed retrospective data on 22 patients with treatment-resistant depression, who failed at least 3 adequate antidepressant treatment trials and 1 adequate trial of repetitive transcranial magnetic stimulation;...
Anesthesiology
July 30, 2017
Kelly Jonkman, Andreas Duma, Erik Olofsen et al.
56 citations
BACKGROUND: Esketamine is traditionally administered via intravenous or intramuscular routes. In this study we developed a pharmacokinetic model of inhalation of nebulized esketamine with special emphasis on pulmonary absorption and bioavailability. METHODS: Three increasing doses of inhaled esketamine (dose escalation from 25 to 100 mg) were applied followed by a single intravenous dose (20...
The Journal of Clinical Psychiatry
July 20, 2017
Chittaranjan Andrade
179 citations
BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine...
July 1, 2017
B. Pradhan, Irving W. Wainer, Ruin Moaddel et al.
Background and objectives: Trauma memories lay at the core in etiopathogenesis of post-traumatic stress disorder (PTSD). Using pharmacological and cognitive behavioral treatments that specifically target trauma memories can improve the outcome. Ketamine has been shown to rapidly improve symptoms in PTSD and comorbid depression, but unfortunately these effects are short-lived. Trauma...
American Journal of Psychiatry
July 1, 2017
S. T. Wilkinson, Mesut Toprak, Mason S. Turner et al.
TO THE EDITOR: Since 2000, several small randomized controlled trials have demonstrated that ketamine has potent and rapid-acting antidepressant effects in patients with treatment-resistant depression (1). Despite a lack of longterm data or Food and Drug Administration indication, many community providers and academic centers have begun offering ketamine treatment to patients with major...
Neurotoxicity Research
July 1, 2017
Jana Ruda-Kucerova, Zuzana Babinska, Tibor Stark et al.
26 citations
Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of...
Frontiers in Cellular Neuroscience
June 28, 2017
Malwina Lisek, Bozena Ferenc, Maciej Studzian et al.
Ketamine causes psychotic episodes and is often used as pharmacological model of psychotic-like behavior in animals. There is increasing evidence that molecular mechanism of its action is more complicated than just N-methyl-D-aspartic acid (NMDA) receptor antagonism and involves interaction with the components of calcium homeostatic machinery, in particular plasma membrane calcium pump (PMCA)....
Cochrane Database of Systematic Reviews
June 28, 2017
Rae Frances Bell, Christopher Eccleston, Eija Kalso
246 citations
BACKGROUND: This is an update of a review first published in 2003 and updated in 2012.Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine is known to have psychomimetic (including...